Racial Disparities in Breast Cancer Diagnosis and Treatment by Hormone Receptor and HER2 Status

被引:112
|
作者
Chen, Lu [1 ,2 ]
Li, Christopher I. [1 ,2 ]
机构
[1] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA
[2] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA
关键词
AFRICAN-AMERICAN WOMEN; HISPANIC WHITE WOMEN; SOCIOECONOMIC-STATUS; RACIAL/ETHNIC DIFFERENCES; SCREENING MAMMOGRAPHY; ETHNIC-DIFFERENCES; INSURANCE STATUS; SURVIVAL; BLACK; STAGE;
D O I
10.1158/1055-9965.EPI-15-0293
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: African American and Hispanic women are more likely to be diagnosed with aggressive forms of breast cancer. Disparities within each subtype of breast cancer have not been well documented. Methods: Using data from 18 SEER cancer registries, we identified 102,064 women aged 20 years or older, diagnosed with invasive breast cancer in 2010-2011, and with known stage, hormone receptor (HR), and HER2 status. Associations between race/ethnicity and cancer stage and receipt of guideline-concordant treatment were evaluated according to HR/HER2 status. Results: Overall, African American and Hispanic women were 30% to 60% more likely to be diagnosed with stage II-IV breast cancer compared with non-Hispanic whites. African American women had 40% to 70% higher risks of stage IV breast cancer across all four subtypes. American Indian/Alaska Native women had a 3.9-fold higher risk of stage IV triple-negative breast cancer. African American and Hispanic whites were 30% to 40% more likely to receive non-guideline-concordant treatment for breast cancer overall and across subtypes. Conclusions: Women in several racial/ethnic groups are more likely to be diagnosed with more advanced stage breast cancer. African American and American Indian/Alaska Native women in particular had the highest risk of being diagnosed with stage IV triple-negative breast cancer. African American and Hispanic women were also consistently at higher risk of not receiving guideline-concordant treatment across subtypes. Impact: These findings provide important characterization of which subtypes of breast cancer racial/ethnic disparities in stage and treatment persist. (C) 2015 AACR.
引用
收藏
页码:1666 / 1672
页数:7
相关论文
共 50 条
  • [21] Clinical Implication of HER2 Status in Hormone Receptor-Positive Mucinous Breast Cancer
    Gwark, Sung-chan
    Lee, Han Shin
    Lee, Youngjoo
    Lee, Sae Byul
    Sohn, Guiyun
    Kim, Jisun
    Chung, Il Yong
    Ko, Beom Seok
    Kim, Hee Jeong
    Son, Byung Ho
    Ahn, Jin-Hee
    Jung, Kyung Hae
    Kim, Sung-Bae
    Lee, Hee Jin
    Gong, Gyung-Yub
    Ahn, Sei Hyun
    Lee, Jong Won
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (07) : 2166 - 2174
  • [22] Clinical Implication of HER2 Status in Hormone Receptor-Positive Mucinous Breast Cancer
    Sung-chan Gwark
    Han Shin Lee
    Youngjoo Lee
    Sae Byul Lee
    Guiyun Sohn
    Jisun Kim
    Il Yong Chung
    Beom Seok Ko
    Hee Jeong Kim
    Byung Ho Son
    Jin-Hee Ahn
    Kyung Hae Jung
    Sung-Bae Kim
    Hee Jin Lee
    Gyung-Yub Gong
    Sei Hyun Ahn
    Jong Won Lee
    Annals of Surgical Oncology, 2019, 26 : 2166 - 2174
  • [23] Characterization of Hormone Receptor and HER2 Status in Breast Cancer Using Mass Spectrometry Imaging
    Goncalves, Juliana Pereira Lopes
    Bollwein, Christine
    Noske, Aurelia
    Jacob, Anne
    Jank, Paul
    Loibl, Sibylle
    Nekljudova, Valentina
    Fasching, Peter A. A.
    Karn, Thomas
    Marme, Frederik
    Mueller, Volkmar
    Schem, Christian
    Sinn, Bruno Valentin
    Stickeler, Elmar
    van Mackelenbergh, Marion
    Schmitt, Wolfgang D. D.
    Denkert, Carsten
    Weichert, Wilko
    Schwamborn, Kristina
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (03)
  • [24] HER2 status and disparities in luminal breast cancers
    Holowatyj, Andreana N.
    Ruterbusch, Julie J.
    Ratnam, Manohar
    Gorski, David H.
    Cote, Michele L.
    CANCER MEDICINE, 2016, 5 (08): : 2109 - 2116
  • [25] Risk of a Second Breast Cancer Associated with Hormone-Receptor and HER2/neu Status of the First Breast Cancer
    Bessonova, Leona
    Taylor, Thomas H.
    Mehta, Rita S.
    Zell, Jason A.
    Anton-Culver, Hoda
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2011, 20 (02) : 389 - 396
  • [26] Racial disparities in attainment of pathological complete responses in HER2 positive breast cancer
    Angell, Callie
    Bullock, Jolonda
    Diaz, Anna
    Basha, Riyaz
    Narra, Kalyani
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2022, 31 (01)
  • [27] Estrogen and progesterone hormone receptor status in HER2 positive breast cancers
    Kubelka-Sabit, K.
    Filipovski, V.
    Karagjozov, M.
    Stojcevska-Capova, M.
    Jasar, D.
    VIRCHOWS ARCHIV, 2015, 467 : S65 - S65
  • [28] Hormone receptor positive, HER2 negative metastatic breast cancer: Future treatment landscape
    Redfern, Andrew
    Burslem, Katie
    Woodward, Natasha
    Beith, Jane
    Mccarthy, Nicole
    De Boer, Richard
    Bell, Richard
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 19 - 31
  • [29] Recent advances in the treatment of hormone receptor positive HER2 negative metastatic breast cancer
    Fedele, Palma
    Orlando, Laura
    Schiavone, Paola
    Calvani, Nicola
    Caliolo, Chiara
    Quaranta, Annamaria
    Nacci, Angelo
    Cinieri, Saverio
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2015, 94 (03) : 291 - 301
  • [30] Clinical implication of HER2/neu status in hormone receptor positive pure mucinous breast cancer
    Gwark, S-C
    Lee, J. W.
    Lee, S. B.
    Sohn, G.
    Kim, J.
    Chung, I. Y.
    Ko, B. S.
    Kim, H. J.
    Son, B. H.
    Ahn, S. H.
    CANCER RESEARCH, 2019, 79 (04)